Related Experiment Video
Updated: Feb 19, 2026
08:38
Author Spotlight: A Neonatal Heterotopic Rat Heart Transplantation Model for the Study of Endothelial-to-Mesenchymal Transition
Published on: July 21, 2023
1.7K
Diffuse neonatal hemangiomatosis presenting as congestive heart failure
Sheetal Agarwal1, Anu Sharma1, Arti Maria2
1Department of Pediatrics, PGIMER and Dr RML Hospital, Delhi, India.
Dermatology Practical & Conceptual
|November 1, 2017
Summary
Diffuse neonatal hemangiomatosis, a rare condition, can cause severe complications. This case highlights successful treatment using decongestive drugs, prednisolone, and propranolol, emphasizing individualized management strategies.
Area of Science:
- Neonatal Medicine
- Pediatric Dermatology
- Vascular Anomalies
Background:
- Diffuse neonatal hemangiomatosis (DNH) is a rare, high-mortality condition.
- DNH can present with extensive cutaneous and visceral hemangiomas.
- Hepatic hemangiomas pose a significant risk of congestive heart failure.
Purpose of the Study:
- To report a case of DNH presenting with congestive heart failure.
- To discuss the management approach for DNH.
- To highlight the need for individualized treatment strategies in DNH.
Main Methods:
- A neonate with approximately 490 cutaneous and multiple liver hemangiomas was treated.
- Initial management included decongestive drugs and prednisolone.
- Propranolol was added later in the treatment course.
Main Results:
- The neonate presented with congestive heart failure due to diffuse hepatic hemangiomas.
- Prompt treatment with decongestive drugs and prednisolone led to a positive response.
- The addition of propranolol further improved the patient's condition and aimed to prevent long-term steroid complications.
Conclusions:
- Successful management of DNH requires prompt and individualized therapeutic interventions.
- A combination of medications, including propranolol, can be effective in treating DNH and its complications.
- Further research is needed to establish a consensus on the optimal initial management of DNH.
Related Concept Videos
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
540
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
540
01:30Cardiomyopathy II: Dilated Cardiomyopathy
622
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
622
01:26Heart Failure III: Clinical Manifestations
661
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
661
01:17Pathophysiology of Heart Failure
4.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.0K
01:20Mitral Regurgitation I: Introduction
654
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
654
01:29Heart Failure II: Pathophysiology
1.0K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.0K